PolyPid Ltd.
corporate_fare Company Profile
PolyPid Ltd. (NASDAQ:PYPD) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 18 items for PYPD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PYPD spans 6-K, 20-F.
Recent high-impact activity:
- PolyPid Posts Q3 Loss of $0.24/Share; Cash to Fund Operations Into 2028 Ahead of Nov 28 PDUFA
- PolyPid Posts Zero Revenue and Wider-Than-Expected Loss in Q3
- PolyPid Adds Kynatrix-Based PD01b for Diabetic Foot Infections to Pipeline
- EMA Validates PolyPid's D-PLEX100 Marketing Application, Starting Formal EU Review
- PolyPid Regains European Rights to D-PLEX100 After ADVANZ PHARMA Deal Ends
Financial Snapshot
Short Interest & Short Volume
3.48 days to coverFINRA reported short interest of 447,180 shares in PYPD as of the October 30, 2026 settlement, a 98.3% increase from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 54.3% of PYPD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
PYPD files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.